Article
Oncology
Semir Vranic, Farhan S. Cyprian, Zoran Gatalica, Juan Palazzo
Summary: Breast cancer, traditionally considered not highly immunogenic, has been found to exhibit immunogenicity in some cases, particularly in aggressive triple-negative types. However, challenges remain in identifying patients who would benefit from immunotherapy and in analyzing samples accurately for immune cell targets. Explore exploration of checkpoint inhibitors in breast cancer, specifically in PD-L1 testing, is an important aspect of current research.
SEMINARS IN CANCER BIOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Steven David, Jennifer Tan, Shankar Siva, Lama Karroum, Peter Savas, Sherene Loi
Summary: Radiotherapy and immunotherapy are gaining attention in solid tumors, including breast cancer. Radiotherapy can activate immune response to treat distant untreated tumors. Stereotactic Ablative Body Radiotherapy is a non-invasive technique that provides high dose ablative treatment while sparing normal tissues.
Review
Pharmacology & Pharmacy
Onyinyechi Obidiro, Gantumur Battogtokh, Emmanuel O. Akala
Summary: Triple negative breast cancer (TNBC) is a subtype of breast cancer that lacks estrogen receptors, progesterone receptors, and human epidermal growth factor receptors. The survival rate for TNBC is generally lower than other subtypes. Chemotherapy is the most common treatment option, but resistance to drugs and off-target toxicity pose challenges. Researchers, clinicians, and pharmaceutical companies must collaborate to develop effective treatments for TNBC. Nanotechnology has shown promise as a potential solution for improving TNBC treatment.
Review
Pharmacology & Pharmacy
Rui Sun, Jiajia Xiang, Quan Zhou, Ying Piao, Jianbin Tang, Shiqun Shao, Zhuxian Zhou, You Han Bae, Youqing Shen
Summary: The enhanced permeability and retention (EPR) effect has been considered the basis of tumor-targeted drug delivery, but its heterogeneity and limitations in clinical practice are now being recognized. Researchers are exploring alternative strategies independent of the EPR effect.
ADVANCED DRUG DELIVERY REVIEWS
(2022)
Review
Pharmacology & Pharmacy
Bilal Zulfiqar, Asim Farooq, Shahzina Kanwal, Kashif Asghar
Summary: Lung cancer is a highly prevalent and deadly disease, often diagnosed at advanced stages. Surgery is not an option at this point, so radiotherapy, chemotherapy, or a combination of both is used. However, these therapies are often ineffective, necessitating the search for alternative preventive approaches. Targeting the tumor microenvironment has proven to be an effective therapy against lung cancer.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Wanting Hou, Yaqin Zhao, Hong Zhu
Summary: Gastric cancer treatment is challenging, but immunotherapy has brought hope to patients. Identifying suitable candidates for treatment and predictive biomarkers is crucial. Multi-omics technologies offer promising platforms for discovering new biomarkers and improving patient selection and treatment outcomes in gastric cancer immunotherapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Cong Zhou, Xiaojiao Cheng, Shuiping Tu
Summary: ICIs are revolutionizing cancer immunotherapy, with significant effects on melanoma and NSCLC. In the case of CRC, patients with high immunogenicity benefit from ICIs, while those with low immunogenicity do not. Ongoing clinical trials aim to improve response to ICIs in CRC patients through better selection and combination strategies.
Review
Multidisciplinary Sciences
Ashley Xu, Thomas R. Kosten
Summary: This review explores the use of antibodies in treating addictions, highlighting both successful cases and areas for improvement, and proposes innovative strategies for future vaccine development. In addition to traditional vaccine research, new approaches such as using adenovirus vectors and designing bivalent vaccines are discussed.
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
(2021)
Review
Immunology
Khadijeh Barzaman, Shima Moradi-Kalbolandi, Aysooda Hosseinzadeh, Mohammad Hossein Kazemi, Hossein Khorramdelazad, Elahe Safari, Leila Farahmand
Summary: The study emphasizes the crucial role of the immune system in breast cancer treatment, and discusses the importance of using various immunotherapy methods in conjunction with traditional chemotherapy to improve patient survival rates, while pointing out the obstacles that still need to be addressed.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Biophysics
Yana Zeng, Donghui Liao, Xiangyang Kong, Qianying Huang, Muyi Zhong, Jianqiang Liu, Alireza Nezamzadeh-Ejhieh, Ying Pan, Hailiang Song
Summary: This review focuses on the recent research progress of zinc-based zeolite imidazole skeleton materials (ZIFs) in the treatment of breast cancer, including targeted drug delivery, photothermal therapy, immunotherapy, and gene therapy.
COLLOIDS AND SURFACES B-BIOINTERFACES
(2023)
Review
Oncology
Vamika Karn, Sandhya Sandhya, Wayne Hsu, Deepak Parashar, Himanshu Narayan Singh, Niraj Kumar Jha, Saurabh Gupta, Navneet Kumar Dubey, Sanjay Kumar
Summary: Cancer is a major cause of death globally, with breast cancer being the most common type affecting women worldwide. Various treatment strategies, including gene therapy using CRISPR/Cas9, are being explored to improve outcomes for breast cancer patients by targeting drug resistance and enhancing immunotherapy.
CANCER CELL INTERNATIONAL
(2022)
Review
Oncology
Wei Xiong, Yunfeng Zhao, He Du, Xuejun Guo
Summary: Immunotherapy has made significant advancements in the treatment of lung cancer, with challenges including the selection of appropriate ICI agents, use of immune biomarkers, and determining the optimal combination and sequence of treatments.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Georgiy Korenev, Sergey Yakukhnov, Anastasia Druk, Anastasia Golovina, Vitaly Chasov, Regina Mirgayazova, Roman Ivanov, Emil Bulatov
Summary: Elevated levels of USP7 are associated with poor survival in many cancers. Inhibition of USP7 can affect the function of regulatory T cells and tumor-associated macrophages, as well as decrease levels of oncogenic markers. The application of USP7 inhibitors, alone or in combination with immunotherapy, has great potential for cancer treatment.
Review
Pharmacology & Pharmacy
Tao Yang, Yilin Xiong, Yufei Zeng, Yan Wang, Jing Zeng, Jie Liu, Shangfu Xu, Li-Sheng Li
Summary: Lung cancer, especially non-small cell lung cancer (NSCLC), is still the leading cause of cancer-related deaths worldwide. Despite some clinical advancements in conventional treatments, the survival rate of NSCLC remains low. In recent years, immunotherapy, including antibody therapy and cell therapy, has emerged as a new frontier in lung cancer research, particularly immune checkpoint inhibitors (ICI). These approaches have significantly improved the survival rate and treatment response in NSCLC patients by enhancing the immune system and targeting tumor cells more effectively. This paper provides a comprehensive review of the relevant targets, clinical progress, and adverse reactions of various immunotherapies, as well as their combination therapies, aiming to offer better treatment options for NSCLC.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Biology
Zhangsong Wu, Jinjian Liu, Ruixiang Dai, Song Wu
Summary: The treatment strategy for bladder cancer has evolved with the introduction of immunotherapy, but only a limited number of patients benefit from it, and there are challenges with immune-related adverse events. If response rates improve and adverse events are managed better, immunotherapy could potentially revolutionize the landscape of urothelial carcinoma therapeutics.
SCIENCE CHINA-LIFE SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Masanori Oshi, Hideo Takahashi, Yoshihisa Tokumaru, Li Yan, Omar M. Rashid, Ryusei Matsuyama, Itaru Endo, Kazuaki Takabe
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2020)
Article
Surgery
Konstantinos Chouliaras, Yoshihisa Tokumaru, Mariko Asaoka, Masanori Oshi, Kristopher M. Attwood, Kazuhiro Yoshida, Takashi Ishikawa, Kazuaki Takabe
Summary: Tumor-associated tissue eosinophilia was observed in 3.7% of breast cancer cases, and was associated with a higher mutation and neoantigen load. It showed lower cytolytic activity score and enriched cell proliferation-related gene sets, suggesting a different role compared to tumor-infiltrating lymphocytes.
Article
Oncology
Masanori Oshi, Yoshihisa Tokumaru, Ankit Patel, Li Yan, Ryusei Matsuyama, Itaru Endo, Matthew H. G. Katz, Kazuaki Takabe
Article
Oncology
Masanori Oshi, Tae Hee Kim, Yoshihisa Tokumaru, Li Yan, Ryusei Matsuyama, Itaru Endo, Leonid Cherkassky, Kazuaki Takabe
Summary: In this study, the relationship between enhancement of DNA repair and cancer aggressiveness, tumor immune microenvironment, and patient survival in hepatocellular carcinoma (HCC) patients was investigated using a DNA repair pathway score. Results showed that the DNA repair pathway was enhanced in a stepwise manner during HCC carcinogenesis, particularly noted in grade 3 tumors. High DNA repair activity in HCC was associated with worse survival, increased intratumor heterogeneity, and mutation load.
Article
Surgery
Lan Le, Yoshihisa Tokumaru, Masanori Oshi, Mariko Asaoka, Li Yan, Itaru Endo, Takashi Ishikawa, Manabu Futamura, Kazuhiro Yoshida, Kazuaki Takabe
Summary: High levels of Th2 are associated with aggressive features and treatment response in ER-positive breast cancer, potentially serving as a biomarker for patient selection for NAC.
Article
Cell Biology
Yoshihisa Tokumaru, Masanori Oshi, Ankit Patel, Wanqing Tian, Li Yan, Nobuhisa Matsuhashi, Manabu Futamura, Kazuhiro Yoshida, Kazuaki Takabe
Summary: Cell proliferation-related gene sets were consistently enriched in both CRC tissues and organoids compared to adenoma tissues and organoids. None of the known pathways in the colon adenoma-carcinoma sequence were consistently enriched in CRC organoids. There was no enrichment of the tumor microenvironment-related gene sets in CRC organoids.
Article
Oncology
Masanori Oshi, Fernando A. Angarita, Yoshihisa Tokumaru, Li Yan, Ryusei Matsuyama, Itaru Endo, Kazuaki Takabe
Summary: The study highlights the significance of neoadjuvant chemotherapy in breast cancer treatment and introduces a novel three-gene score that correlates with pathological complete response and survival. The high-score triple-negative breast cancer patients showed better response to chemotherapy and improved survival outcomes. The three-gene score is associated with high mutation rate, immune cell infiltration, and predicts response to neoadjuvant chemotherapy in triple-negative breast cancer patients.
Article
Oncology
Masanori Oshi, Michelle R. Huyser, Lan Le, Yoshihisa Tokumaru, Li Yan, Ryusei Matsuyama, Itaru Endo, Kazuaki Takabe
Summary: The abundance of microvascular endothelial (mvE) cells in colorectal cancer is associated with mature blood vessels in the tumor microenvironment and can predict response to chemotherapy and patient survival.
Article
Cell Biology
Masanori Oshi, Yoshihisa Tokumaru, Swagoto Mukhopadhyay, Li Yan, Ryusei Matsuyama, Itaru Endo, Kazuaki Takabe
Summary: ANXA1 is overexpressed in pancreatic cancer and associated with cell proliferation, survival, and drug response. High ANXA1 expression is associated with specific cell types in the tumor microenvironment and multiple malignant gene sets.
Article
Multidisciplinary Sciences
Yoshihisa Tokumaru, Masanori Oshi, Michelle R. Huyser, Li Yan, Masahiro Fukada, Nobuhisa Matsuhashi, Manabu Futamura, Yukihiro Akao, Kazuhiro Yoshida, Kazuaki Takabe
Summary: The study found that low expression of miR-29a is associated with aggressive cancer biology and worse survival in gastric cancer patients, serving as an independent prognostic biomarker of poor overall survival and disease-specific survival.
SCIENTIFIC REPORTS
(2021)
Article
Multidisciplinary Sciences
Masanori Oshi, Yoshihisa Tokumaru, Fernando A. Angarita, Lan Lee, Li Yan, Ryusei Matsuyama, Itaru Endo, Kazuaki Takabe
Summary: Adipogenesis in breast cancer, particularly in triple negative breast cancer (TNBC), is associated with poorer survival, different tumor metabolism, and an unfavorable tumor immune microenvironment, which is distinct from the abundance of adipocytes.
SCIENTIFIC REPORTS
(2021)
Review
Oncology
Vijayashree Murthy, Jessica Young, Yoshihisa Tokumaru, Marie Quinn, Stephen B. Edge, Kazuaki Takabe
Summary: This article reviews different options to identify positive lymph nodes at the time of definitive surgery, aiming to determine pathological response after neoadjuvant therapy and achieve optimal surgical outcomes with minimal complications.
Review
Oncology
Masanori Oshi, Vijayashree Murthy, Hideo Takahashi, Michelle Huyser, Maiko Okano, Yoshihisa Tokumaru, Omar M. Rashid, Ryusei Matsuyama, Itaru Endo, Kazuaki Takabe
Summary: Liquid biopsy, including urine analysis, has become a popular and less invasive method for detecting circulating tumor cells and nucleic acids in cancer patients. It allows for longitudinal repeat sampling and can provide real-time information on tumor evolution, making it a powerful tool for diagnosis and treatment monitoring in both urological and non-urological cancers. Advances in extraction methods of urinary substances have shown close relationships with carcinogenesis, metastasis, and therapeutic response in various types of cancers.
Article
Oncology
Rongrong Wu, Arya Mariam Roy, Yoshihisa Tokumaru, Shipra Gandhi, Mariko Asaoka, Masanori Oshi, Li Yan, Takashi Ishikawa, Kazuaki Takabe
Summary: Tumor dormancy is an important mechanism for late breast cancer recurrence. This study investigates the clinical relevance of NR2F1 expression, a known biomarker for dormancy. The results show that high NR2F1 expression in breast cancer is associated with enriched metastasis and stem cell-related pathways, as well as suppressed cell proliferation. Furthermore, NR2F1 is predominantly expressed in cancer-associated fibroblasts, rather than in cancer cells.
Review
Oncology
Irene Yu, Rongrong Wu, Yoshihisa Tokumaru, Krista P. Terracina, Kazuaki Takabe
Summary: This manuscript provides a comprehensive review of the gut microbiome's impact on colorectal cancer, exploring microbial mechanisms, treatment advancements, potential options for diagnosis and prevention, and future research directions.
